Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 5Colorectal Neoplasms 4Hematologic Neoplasms 3Prostatic Neoplasms 2Motor Activity 2Lung Neoplasms 2Hodgkin Disease 2Hematopoietic and Lymphoid System Neoplasm 2Carcinoma, Non-Small-Cell Lung 2Trastuzumab Cardiotoxicity 1Stress Disorders, Post-Traumatic 1Sleep Wake Disorders 1Sedentary Behavior 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Obesity 1Neoplasms 1Neoplasm Metastasis 1Myocardial Fibrosis 1Multiple Endocrine Neoplasia Type 1 1Lymphoma, Follicular 1Insulin Resistance 1Hereditary Breast and Ovarian Cancer Syndrome 1Heart Diseases 1Head and Neck Neoplasms 1Gastrointestinal Diseases 1Fatigue 1Esophageal Neoplasms 1Dyslipidemias 1Depression 1

Interventions

Exercise Test 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Trastuzumab Cardiotoxicity × Exercise Test × Clear all
NCT02615054 2024-04-11

Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors

Memorial Sloan Kettering Cancer Center

Completed
58 enrolled
Breast

Trastuzumab Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡